We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
12/4/2017 09:47 | Large buy by the chariman a positive signal IMHO. Latest Equity Development article on Ergomed titled '£70m contracted revenues still to come' with target price of up to 437p. Zoptrex phase III results should be out in April and hoping this will give the share price the next boost up. | mfhmfh | |
04/4/2017 15:56 | Thanks for that Timbo. Very large buy today from Chairman Peter George. "Ergomed, a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that on 3 April 2017, Mr Peter George, Chairman of the Company, bought 100,000 ordinary shares of 1p each in the Company ("Share(s)") at a price of 190p per Share." hxxp://www.investega | bermudashorts | |
03/4/2017 08:57 | Given today's RNS, I thought I remind myself what Sepranolone is all about The partner's Web site is here: Sepranolone is the latest addition to the development portfolio (acquired at the end of last year), so worth a re-read of the Equity Development note that was issued following the Sepranolone deal: On 1st November 2016, Ergomed announced a new co-development partner, Asarina Pharma AB, for the Phase IIb clinical trial (multi-centre, multinational, randomised trial to start in 2017) of Sepranolone (UC1010) as a targeted treatment for patients with premenstrual dysphoric disorder (PMDD). Ergomed will co-invest, conducting the clinical trial. In return Ergomed will receive an equity stake in Asarina. Asarina recently raised €7m (2nd Nov 2016) to invest further in its therapy. PMDD is the most severe form of Premenstrual Syndrome affecting c3-8% of all women and can include regular monthly symptoms of depression, anxiety, irritability, mood changes and loss of emotional control. These symptoms tend to happen in the latter, luteul, part of the menstrual cycle and lasts until the start of the woman’s period. Current treatment ranges from anti-depressants, oral contraceptives, mood stabilisers used in bipolar disorder, chemical menopause, and hysterectomy. There is increasing awareness around this disease and recognition that treatment is beneficial, though not specific to the indication unlike Sepranolone. Asarina’s therapeutics, Sepranolone, is a proprietary, first-in-class, endogenous, small molecule, that acts as a GABA-A modulating steroid antagonist (GAMSA). Sepranolone is the first product developed exclusively for PMDD. To date, Asarina has completed an exploratory, double-blind, randomised, placebo-controlled, clinical phase I/II study involving 120 women with PMDD to evaluate the safety, efficacy and pharmacokinetics of Sepranolone. The study showed good safety and tolerability, and a statistically significant improvement in PMDD symptoms compared to placebo. The drug is currently delivered subcutaneously, and the downsides of this inconvenient route were considered to be outweighed by the benefits from symptomatic relief seen by the clinical trial participants. Asarina are developing a follow on that will look at alternate, more convenient, oral, delivery routes. With a share of the business, Ergomed could see further upside from an oral delivery route. This is yet to be included in the valuation. | timbo003 | |
22/3/2017 10:09 | If you would like to hear management present the preliminary results for the year ended 31 December 2016 for Ergomed we will be hosting a webinar on Wednesday 29th March at 1:45pm. The presentation will last approximately 30 mins and there will then be an opportunity for Q&A. To join please register at: hxxps://attendee.got If you would like to submit any questions for management ahead of the meeting please send them to hannah@equitydevelop Kind regards, The Equity Development Team | hannahh | |
17/3/2017 16:24 | No idea why. Results 'end of March' according to last tarding update. I think stop losses activated. Broker target prices vary between 275 (lowest) and 315 (highest). I'll be buying on Monday. | mfhmfh | |
17/3/2017 16:14 | Any reason for the dip?? | battlebus2 | |
17/3/2017 16:12 | Great buying opportunity. IMHO. | mfhmfh | |
15/3/2017 13:04 | Ergomed will be at the Proactive investor's evening on May 18th, I've booked my place. | timbo003 | |
22/2/2017 09:42 | Ergomed are attending Bio Europe - in Barcelona in March. They are listed as an investor so I guess on the look out for new co development opportunities. hxxps://ebdgroup.kne | bermudashorts | |
20/2/2017 11:44 | More on Modus hxxp://labiotech.eu/ | bermudashorts | |
20/2/2017 08:40 | Thanks for links. I really haven't looked closely enough at Ergomed's development partners but Modus looks very promising. Didn't realise that is was a spin out from the highly prestigious Karolinska Institutet and was funded primarily by the Karolinska Development Fund. Sevuparin has Orphan Drug Status in both Europe and the US. Let's hope it lives up to its promise as Sickle Cell is a dreadfully painful disease with very poor treatment options. | bermudashorts | |
20/2/2017 07:49 | Here's the home page and press release from Modus: Referring to the Numis initiation note (Oct 2016), Ergomed owned 5% of the equity (estimate) in Modus who's principle asset is Sevuparin for the treatment of Sickle cell disease. Peak sales potential for Sevuparin are >$1Bn and it could launch in 2019 - 2020, they have assigned a 16% chance of success and a risk adjusted NPV of £10M based on risk adjusted DCF which comes out at equivalent to 25p/share for Ergomed. | timbo003 | |
20/2/2017 07:19 | Modus raises £2.9 million... | battlebus2 | |
07/2/2017 07:28 | thank you Timbo i hope you do not mind i quoted your 105, in an answer to a question on LSE tks mfhmfh | carnivale | |
06/2/2017 23:56 | 'Numis today reaffirms its buy investment rating on Ergomed Plc (LON:ERGO) and set its price target at 277p.' Equity development: '. A sum-of-the-parts valuation analysis suggests that the Services businesses are valued at c.202p / share. With the Products businesses added to this, the group valuation increases to 301p / share.' 'Stifel today reaffirms its buy investment rating on Ergomed Plc (LON:ERGO) and raised its price target to 315p (from 300p).' | mfhmfh | |
06/2/2017 09:55 | Timbo, Thanks - good stuff. | bermudashorts | |
06/2/2017 08:39 | >>>>BS Yes, that is my understanding, they get a fixed share of all payments and they contribute a fixed share of future development costs. Numis estimate Ergomed's share of Lorediplon at 10% (uncapped) | timbo003 | |
06/2/2017 08:36 | speaking from a medical background this lorideplon RNS is very good news. exciting share to be in right now. IMHO. | mfhmfh | |
06/2/2017 08:21 | Yes really good news, and interesting comments re. valuation of Lorediplon. Ferrer have already licensed Lorediplon to Ildong in Eastern Asia and today have said:- "we will seek to advance the product towards the market through additional partnerships" I'm not sure of the terms of Ergomed's agreement with Ferrer but presumably, if any further licensing deals are struck, Ergomed would be entitled to a cut of any upfront payments? | bermudashorts | |
06/2/2017 08:05 | Whilst on the subject of Numis valuation’s, the other valuations and probabilities of obtaining regulatory approval are as follows: PeproStat: 29p ( 27%) Ready Flow: 7p (5%) Lorediplon: (see above) Zoptrex: 45p (40%) Multikine: 0p Sevuparin: 25p (16%) | timbo003 | |
06/2/2017 07:43 | Today's news has prompted me to look at the Numis research note (October 2016) referred to in my earlier posts Numis were valuing Lorediplon as worth 29p/share before this result (risk adjusted with 25% chance of success), furthermore they estimate that Neurology compounds generally have a probability of 50% of getting approval (following a successful phase II), so they will presumably now value Loredipion at 58p/share. Oh happy days! | timbo003 | |
06/2/2017 07:13 | Excellent news | battlebus2 | |
01/2/2017 14:24 | Tks mfhmfh i thought so and i put my toe in yesterday and today ... | carnivale | |
01/2/2017 08:33 | definitively positive RNS yesterday. no idea what impact it will have on earning/sp though. I still thinks Haemostatix is the potentially 'big one'. All IMHO. | mfhmfh |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions